| Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) | — | University of Southern California | <1 mi |
| Longitudinal Early-onset Alzheimer's Disease Study Protocol | — | Indiana University | <1 mi |
| Dominantly Inherited Alzheimer Network (DIAN) | — | Washington University School of Medicine | <1 mi |
| A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | Phase 3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | <1 mi |
| Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | Phase 3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | <1 mi |
| Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies | Phase 3 | Hoffmann-La Roche | <1 mi |
| Sirtuin-NAD Activator in Alzheimer's Disease | Phase 1/2 | Brigham and Women's Hospital | <1 mi |
| Gamma-Music Based Intervention for Mild Alzheimer's Disease | N/A | Northeastern University | <1 mi |
| A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study) | Phase 1/2 | AC Immune SA | <1 mi |
| Triage Survey for Neurology Research Eligibility | — | Adams Clinical | <1 mi |
| Assess Fibrin in Brains With AD/ADRD | Phase 1/2 | Massachusetts General Hospital | <1 mi |
| Mindfulness for Cognition in Early-stage Alzheimer's Disease | N/A | VA Boston Healthcare System | <1 mi |
| Transcranial Magnetic Stimulation Treatment for Alzheimer's Disease | Early 1 | Massachusetts General Hospital | <1 mi |
| Improving Memory in Alzheimer's Disease With Noninvasive Brain Stimulation | N/A | Boston University Charles River Campus | <1 mi |
| A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia | Phase 2 | Intra-Cellular Therapies, Inc. | <1 mi |
| Cognitive Neurology Unit Clinical Registry | — | Beth Israel Deaconess Medical Center | <1 mi |
| A Study To Assess The Feasibility Of Indivi Mobile Application In Monitoring Cognitive Performance In Aging Population | — | Indivi AG | <1 mi |
| TMS for Cognitive Decline in Aging and Preclinical AD | N/A | Massachusetts General Hospital | <1 mi |
| Gamma Light and Sound Stimulation to Prevent Dementia in Cognitively Normal People At Risk for Alzheimer's Disease | N/A | Massachusetts General Hospital | <1 mi |
| Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease | Phase 2 | Brigham and Women's Hospital | <1 mi |
| Digital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD | — | Massachusetts General Hospital | <1 mi |
| Trial to Reduce Antimicrobial Use in Nursing Home Residents With Alzheimer's Disease and Other Dementias 2.0 | N/A | Hebrew SeniorLife | <1 mi |
| Trial-Ready Cohort-Down Syndrome (TRC-DS) | — | University of Southern California | <1 mi |
| Pilot Study of a Brain Health Program in Senior Centers | N/A | Massachusetts General Hospital | <1 mi |
| Non-invasive Brain Stimulation for Cognitive and Motor Dysfunction in Dementia | N/A | Hebrew SeniorLife | <1 mi |
| Tau PET/CT Imaging in the Mismatch Prospective Cohort Study (MPC-TAU) | — | University of Pennsylvania | <1 mi |
| Treating Hyperexcitability in AD With Levetiracetam | Phase 2 | Beth Israel Deaconess Medical Center | <1 mi |
| Contributions of mTBI to Neurodegeneration Due to Chronic Traumatic Encephalopathy (CTE) and Alzheimer's Disease (AD) | — | VA Office of Research and Development | <1 mi |
| Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant | Phase 3 | Eidos Therapeutics, a BridgeBio company | <1 mi |
| PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases | Phase 1/2 | Brigham and Women's Hospital | <1 mi |
| The Wandering Nerve: Gateway to Boost Alzheimer's Disease Related Cognitive Performance | N/A | Massachusetts General Hospital | 1 mi |
| Individual Closed-Loop Neuromodulation Therapy for Alzheimer's Disease | N/A | Massachusetts General Hospital | 1 mi |
| A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease | Phase 1 | Eli Lilly and Company | 1 mi |
| Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy | N/A | Massachusetts Institute of Technology | 3 mi |
| Gamma Frequency Stimulation in Individuals With Down Syndrome | N/A | Massachusetts Institute of Technology | 3 mi |
| Brain Effects of Gamma Frequency Sensory Stimulation (40Hz Light, Sound and Other Devices) | Phase 2 | Massachusetts Institute of Technology | 3 mi |
| Home-Based Brain Stimulation for Motoric Cognitive Risk Syndrome | N/A | Hebrew SeniorLife | 6 mi |
| A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) | Phase 3 | Bristol-Myers Squibb | 6 mi |
| A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | Phase 3 | Hoffmann-La Roche | 6 mi |
| Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia | Early 1 | Mclean Hospital | 7 mi |
| Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside | — | Mclean Hospital | 7 mi |
| Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD) | N/A | Brent Forester | 7 mi |
| Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia | Early 1 | Mclean Hospital | 7 mi |
| The BRAIN App (Phase 2 SBIR) | N/A | Hopeful Aging | 8 mi |
| A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease | Phase 3 | Bristol-Myers Squibb | 8 mi |
| A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) | Phase 3 | Bristol-Myers Squibb | 8 mi |
| A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) | Phase 3 | Bristol-Myers Squibb | 8 mi |
| A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | Phase 3 | Hoffmann-La Roche | 8 mi |
| A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004) | Phase 2 | Merck Sharp & Dohme LLC | 8 mi |
| A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam) | Phase 2 | Alzheimer's Disease Cooperative Study (ADCS) | 9 mi |
| Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease | Phase 2 | University of Arizona | 9 mi |
| Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives | — | Sanguine Biosciences | 9 mi |
| [18F]PI-2620 Phase 3 Histopathological Study | Phase 3 | Life Molecular Imaging Ltd | 11 mi |
| A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD | Phase 3 | Annovis Bio Inc. | 23 mi |
| A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease | Phase 2 | Novartis Pharmaceuticals | 26 mi |
| A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2) | Phase 3 | Bristol-Myers Squibb | 39 mi |
| Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type | Phase 2 | Teikoku Pharma USA, Inc. | 39 mi |
| Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease | Phase 2 | Celgene | 41 mi |
| Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia | — | GAP Innovations, PBC | 41 mi |
| Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD | Phase 1 | Butler Hospital | 41 mi |
| A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation | Phase 2/3 | Washington University School of Medicine | 41 mi |
| Health Behavior Change in Midlife Adults at Risk for Alzheimer's Disease | N/A | Rhode Island Hospital | 41 mi |
| A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation | Phase 2/3 | Washington University School of Medicine | 41 mi |
| Clinical Trial on Agitation in Alzheimer's Dementia | Phase 2 | IGC Pharma, LLC | 41 mi |